

**"Histological and Immunohistochemical study on the possible role of suramin in the healing of experimentally induced laceration of skeletal muscle"**

**Thesis**

**Submitted for Partial Fulfillment of the M.D. Degree in Histology**

**By**

**Waleed Mohammad El-Sherbiny El-Helaly**

*M.Sc.*

*Faculty of Medicine – Misr University for Science and Technology (MUST)*

**Under the Supervision of**

**Professor Dr. Naglaa Medhat Ibrahim Abou-Rabia**

*Professor of Histology*

*Faculty of Medicine*

*Ain shams University*

**Professor Dr. Dina Mohammad Radwan**

*Professor of Histology*

*Faculty of Medicine*

*Cairo University*

**Dr. Lamiaa Ibrahim Abd-Elfattah**

*Assistant Professor of Histology*

*Faculty of Medicine*

*Cairo University*

***Cairo University***

**2014**

# ACKNOWLEDGMENT

I am not only deeply indebted to Professor Dr. Naglaa Medhat Abou-Rabia (professor of histology at Ain Shams University) for suggesting, planning and supervising this work, but also grateful for her continuous scientific guidance, sustained support and encouragement throughout this work.

I would like to express my deepest gratitude to Professor Dr. Dina Mohammad Radwan (professor of histology at Cairo University) for her directions, great support, accuracy and valuable suggestions throughout this study.

I would like to convey my sincere appreciation to Dr. Lamiaa Ibrahim Abdel-Fattah (assistant professor of histology at Cairo University) for her useful scientific help and advice which enabled me to complete this work.

# List of Contents

<b>1. Introduction and aim of work.....</b>	<b>1</b>
<b>2. Review of literature:.....</b>	<b>3</b>
❖ <u>The skeletal muscle</u> .....	3
• Skeletal muscle development (myogenesis) .....	3
• Adult skeletal muscle characteristics.....	5
• Mechanism of skeletal muscle contraction.....	13
• Types of muscle contractions.....	14
❖ <u>Muscle injuries</u> .....	16
• Types of skeletal muscle injuries.....	16
• The patho-biology of muscle injuries.....	17
• Vascularization of the injured muscle.....	24
• Regeneration of the intramuscular nerves.....	25
• Regeneration of the skeletal muscle in relation to age.....	25
• Clinical classification of muscle injuries.....	25
• Diagnosis of muscle injuries.....	26
• Treatment principles of muscle injuries.....	27
❖ <u>Satellite cells</u> .....	32
• Adult muscle stem cells.....	32
• Identification of muscle satellite cells.....	32
• Embryonic origin of muscle satellite cells.....	33
• Dynamics of muscle satellite cells.....	34
• Multipotentiality of muscle satellite cells.....	34
• Satellite cells in muscle repair.....	35
❖ <u>Regulation of skeletal muscle regeneration</u> .....	38
• The satellite cell niche.....	38

• Growth factors.....	39
❖ <u>Vimentin and suramin</u> .....	46
<b>3. Material and methods</b> .....	50
<b>4. Results</b> .....	60
<b>5. Discussion</b> .....	164
<b>6. Summary and conclusion</b> .....	176
<b>7. Recommendations</b> .....	179
<b>8. References</b> .....	180
<b>9. Arabic summary</b>	

# List of Abbreviations

<b><math>\alpha</math> -SMA</b>	Alpha smooth muscle actin
<b>A bands</b>	Anisotropic bands
<b>ab</b>	Abjunctional stump
<b>ad</b>	Adjunctional stump
<b>BM</b>	Basal membrane
<b>BMPs</b>	Bone morphogenetic proteins
<b>cz</b>	Central zone
<b>DG</b>	Dystroglycans
<b>ECM</b>	Extracellular connective tissue matrix
<b>FDA</b>	Food and drug administration
<b>FGF</b>	Fibroblast growth factor
<b>FGF-2 and -6</b>	Fibroblast growth factor-2 and 6
<b>GFAP</b>	Glial fibrillary acidic protein
<b>GM</b>	Gastrocnemius muscle
<b>H&amp;E</b>	Hematoxylin and eosin
<b>HGF</b>	Hepatocyte growth factor
<b>I bands</b>	Isotropic bands
<b>IF</b>	Intermediate filament
<b>IFP</b>	Intermediate filament protein
<b>IGF</b>	Insulin-like growth factor
<b>INF-<math>\gamma</math></b>	Interferon gamma

<b>MCK</b>	Muscle creatine kinase
<b>MCN</b>	Myocyte nucleus
<b>MDSCs</b>	Muscle-derived stem cells
<b>MHC</b>	Myosin heavy chain
<b>MMP-2 and -9</b>	Matrix metalloproteinases-2 and -9
<b>MRFs</b>	Myogenic regulatory factors
<b>MSTN</b>	Myostatin
<b>MTJs</b>	Myotendinous junctions
<b>MYF5</b>	Myogenic factor 5 protien
<b>MYOD</b>	Myogenic differentiation protien
<b>NMJs</b>	Neuromuscular junctions
<b>NSAIDs</b>	Non-steroidal anti inflammatory drugs
<b>Pax3</b>	Paired box 3 gene
<b>Pax7</b>	Paired box 7 gene
<b>PBS</b>	Phosphate buffered saline
<b>PDGF-AA and BB</b>	Platelet-derived growth factor-AA and –BB
<b>RICE</b>	Rest, ice, compression and elevation principle
<b>rz</b>	Regeneration zone
<b>SCs</b>	Satellite cells
<b>SG</b>	Sarcoglycans
<b>SHH</b>	Sonic hedgehog protien
<b>SP cells</b>	Side population cells

<b>SR</b>	Sarcoplasmic reticulum
<b>SYN</b>	Syntrophins
<b>sz</b>	Survival zone
<b>T tubules</b>	Transverse tubules
<b>TGF-<math>\alpha</math></b>	Transforming growth factor- $\alpha$
<b>TGF-<math>\beta</math>1</b>	Transforming growth factor- $\beta$ 1
<b>TN-C</b>	Tenascin-C
<b>V phenotype</b>	Vimentin phenotype
<b>VAD phenotype</b>	Vimentin, $\alpha$ -SMA, and desmin phenotype
<b>VADM phenotype</b>	Vimentin, $\alpha$ -SMA, desmin and myosin heavy chains phenotype
<b>VD phenotype</b>	Vimentin and desmin phenotype
<b>VEGF</b>	Vascular endothelial growth factor
<b>WNTS</b>	Wingless/integrated protien

# List of Diagrams

<b>Diagram (1)</b>	A schematic presentation of a 4-week old human embryo showing somites.....	3
<b>Diagram (2)</b>	A schematic presentation showing the maturation and compartmentalization of somites.....	3
<b>Diagram (3A,B)</b>	A schematic presentation showing the signaling factors and cellular events involved in embryonic skeletal muscle formation.....	4
<b>Diagram (4)</b>	Schematic drawing of the structural design of skeletal muscle.....	5
<b>Diagram (5)</b>	A schematic presentation of myofiber–extracellular matrix (ECM) adhesion.....	7
<b>Diagram (6)</b>	Schematic presentation of the T-tubules and sarcoplasmic reticulum.....	9
<b>Diagram (7)</b>	A schematic presentation & an electron micrograph of the myofibril showing its different zone.....	10
<b>Diagram (8A,B)</b>	A schematic presentation for a cross view in the different zones of a myofibril.....	11
<b>Diagram (9)</b>	A schematic presentation of the molecular structure of the myofilaments.....	12
<b>Diagram (10)</b>	A schematic presentation for the mechanism of skeletal muscle contraction.....	13
<b>Diagram (11)</b>	A schematic presentation of the sliding filament model of contraction in the three different types of muscle contraction.....	15
<b>Diagram (12)</b>	A schematic presentation of a shearing injury of skeletal muscle.....	18
<b>Diagram (13)</b>	A schematic illustration of the healing skeletal muscle at different times.....	20
<b>Diagram (14)</b>	A schematic presentation of symmetric and asymmetric division of satellite cells.....	36
<b>Diagram (15)</b>	A schematic presentation of the satellite cell niche and regulatory factors.....	38
<b>Diagram (16)</b>	A schematic presentation showing the (TGF)- $\beta$ pathway.....	43
<b>Diagram (17)</b>	A schematic presentation of an IF coiled-coil dimer as exemplified by vimentin...	46



# List of Figures

<b>Fig 1</b>	Laceration injury model.....	53
<b>Fig 2 (A,B)</b>	Gastrocnemius muscle excision.....	54
<b>Fig 3</b>	Photomicrograph showing fibroblasts strongly positive for vimentin, skeletal muscle fibers are negative for vimentin.....	58
<b>Fig 4 (A,B,C)</b>	Group I→H&E.....	63,65
<b>Fig 5 (A,B)</b>	Group I→M.T.....	67
<b>Fig 6 (A,B)</b>	Group I→Anti-vimentin.....	69
<b>Fig 7 (A,B,C)</b>	Group II→H&E.....	73,75
<b>Fig 8 (A,B)</b>	Group II→M.T.....	77
<b>Fig 9 (A,B)</b>	Group II→Anti-vimentin.....	79
<b>Fig 10 (A,B,C)</b>	Group IIIA→H&E.....	83,85
<b>Fig 11 (A,B)</b>	Group IIIA→M.T.....	87
<b>Fig 12 (A,B)</b>	Group IIIA→Anti-vimentin.....	89
<b>Fig 13 (A,B,C)</b>	Group IIIB→H&E.....	93,95
<b>Fig 14 (A,B)</b>	Group IIIB→M.T.....	97
<b>Fig 15 (A,B)</b>	Group IIIB→Anti-vimentin.....	99
<b>Fig 16 (A,B,C)</b>	Group IIIC→H&E.....	103,105
<b>Fig 17 (A,B)</b>	Group IIIC→M.T.....	107
<b>Fig 18 (A,B)</b>	Group IIIC→Anti-vimentin.....	109
<b>Fig 19 (A,B,C)</b>	Group IVA→H&E.....	113,115
<b>Fig 20 (A,B)</b>	Group IVA→M.T.....	117
<b>Fig 21 (A,B)</b>	Group IVA→Anti-vimentin.....	119
<b>Fig 22 (A,B,C)</b>	Group IVB→H&E.....	123,125
<b>Fig 23 (A,B)</b>	Group IVB→M.T.....	127
<b>Fig 24 (A,B)</b>	Group IVB→Anti-vimentin.....	129

# List of Tables

<b>Table 1:</b>	Key growth factors regulating skeletal muscle regeneration.....	42
<b>Table 2:</b>	Method of preparing the anesthetic cocktail.....	52
<b>Table 3:</b>	Results of post hoc comparisons of Group II&V versus Group.....	143
<b>Table 4:</b>	Results of post hoc comparisons of Group II&V versus Group III A.....	144
<b>Table 5:</b>	Results of post hoc comparisons of Group II&V versus Group III B.....	145
<b>Table 6:</b>	Results of post hoc comparisons of Group II&V versus Group III C.....	146
<b>Table 7:</b>	Results of post hoc comparisons of Group II&V versus Group IV A.....	147
<b>Table 8:</b>	Results of post hoc comparisons of Group II&V versus Group IV B.....	148
<b>Table 9:</b>	Results of post hoc comparisons of Group III A versus Group III B.....	149
<b>Table 10:</b>	Results of post hoc comparisons of Group III A versus Group III C.....	150
<b>Table 11:</b>	Results of post hoc comparisons of Group III A versus Group IV A.....	151
<b>Table 12:</b>	Results of post hoc comparisons of Group III A versus Group IV B.....	152
<b>Table 13:</b>	Results of post hoc comparisons of Group III A versus Group.....	153
<b>Table 14:</b>	Results of post hoc comparisons of Group III B versus Group III C.....	154
<b>Table 15:</b>	Results of post hoc comparisons of Group III B versus IV A.....	155
<b>Table 16:</b>	Results of post hoc comparisons of Group III B versus IV B.....	156
<b>Table 17:</b>	Results of post hoc comparisons of Group III B versus Group.....	157
<b>Table 18:</b>	Results of post hoc comparisons of Group III C versus Group IV A.....	158
<b>Table 19:</b>	Results of post hoc comparisons of Group III C versus Group IV B.....	159
<b>Table 20:</b>	Results of post hoc comparisons of Group III C versus Group.....	160
<b>Table 21:</b>	Results of post hoc comparisons of Group IV A versus Group IV B.....	161
<b>Table 22:</b>	Results of post hoc comparisons of Group IV A versus Group.....	162
<b>Table 23:</b>	Results of post hoc comparisons of Group IV B versus Group.....	163

# List of Histograms

<b>Histogram 1:</b>	Box plot showing number of centro-nucleated fibers in the seven studied groups.....	137
<b>Histogram 2:</b>	Box plot showing diameter of centro-nucleated fibers in the seven studied groups.....	138
<b>Histogram 3:</b>	Box plot showing area of collagen fibers in the seven studied groups.....	139
<b>Histogram 4:</b>	Box plot showing area percent of collagen fibers in the seven studied groups...	140
<b>Histogram 5:</b>	Box plot showing vimentin immuno-stained area in the seven studied groups..	141
<b>Histogram 6:</b>	Box plot showing percentage of vimentin immuno-stained area in the seven studied groups.....	142

# **Abstract**

## **Background:**

Skeletal muscle injuries are one of the most frequently occurring injuries in sports medicine. Although these injuries are capable of healing, incomplete functional recovery often occurs due to excessive scar tissue formation.

## **Hypothesis:**

Suramin enhances muscle healing by both stimulating muscle regeneration and preventing fibrosis in lacerated skeletal muscle.

## **Study Design:**

Controlled laboratory study.

## **Methods:**

In vivo: a single concentration of suramin was injected in the gastrocnemius muscle of mice at variable timing after muscle laceration injury. Muscle regeneration and scar tissue formation were evaluated by histologic and immunohistochemical analysis.

## **Results:**

Suramin treatment significantly promoted muscle regeneration, decreased fibrosis formation when introduced after laceration injury.

## **Conclusion:**

Intramuscular injection of suramin after a laceration injury in a multiple dose manner improved overall skeletal muscle healing in comparison to single dose administration

## **Clinical Relevance:**

These findings could contribute to the development of biological treatments to aid in muscle healing after experiencing a muscle injury.

## **Keywords:**

Muscle laceration injury, Suramin, TGF $\beta$ 1, Myostatin, Muscle regeneration, Fibrosis

## **Introduction**

Skeletal muscle injuries, including contusion, strain, or laceration, are the most common injuries occurring in sports, with an incidence varying from 10% to 55% of all the sustained injuries (**Beiner and Joki, 2001**). The healing of an injured skeletal muscle follows a fairly constant pattern irrespective of the underlying cause, such pattern has been described to occur in three phases: 1. *Destruction phase*: characterized by the rupture and consequent necrosis of the myofibers, the formation of a hematoma between the ruptured muscles stumps and the inflammatory cell reaction, 2. *Repair phase*: consisting of the phagocytosis of the necrotized tissue, the regeneration of the myofibers, and the concomitant capillary ingrowth, as well as the production of a connective tissue scar into the injured area; 3. *Remodeling phase*: a period during which the maturation of the regenerated myofibers, the contraction and reorganization of the scar tissue, and the recovery of the functional capacity of the muscle occur. The latter two phases, *repair* and *remodeling*, are usually closely associated or overlapping (**Järvinen et al ., 2005**).

However, the healing process is slow and often incomplete because of the over deposition of collagen leading to significant fibrous scarring that frequently results in functional and structural deficits, contraction injury, muscle atrophy and pain. Therefore a major concern of researchers is how to improve the healing process in the direction of minimizing scar formation in order to overcome these complications (**Huard et al., 2002**).

Growth factors are small peptides that bind to membrane receptors to influence the various steps of the growth and development of cells through several signaling pathways (**Menetrey et al ., 2000**). A large number of growth factors and cytokines are known to be expressed in the injured skeletal muscle, such as the members of fibroblast growth factor(**FGF**), insulin-like growth factor(**IGF**), and transforming growth factor- $\beta$ 1(**TGF- $\beta$ 1**) families (**Bunn et al ., 2004**).

Some of them are powerful stimulators for myogenic precursor cells differentiation and the later fusion of myotubes into multinucleated mature myofibers during the regeneration process, while others such as **(TGF- $\beta$ 1)** are inhibitory for both differentiation and fusion of myoblasts (**Menetrey et al ., 2000**).

Many authors reported that the overproduction of **(TGF- $\beta$ 1)** in response to injury and disease triggers fibrosis via the activation of extracellular matrix production and connective tissue proliferation both in animals and humans (**Li et al ., 2004**).

In light of the apparent role of **TGF- $\beta$ 1** in skeletal muscle fibrosis, **Li and Haurd (2002)** succeeded to improve muscle structure and function by the direct injection of the **TGF- $\beta$ 1** antagonists, as decorin and gamma interferon, into the lacerated muscle blocking its fibrotic effect. However side effects are usually observed with gamma interferon, also decorin is not a clinically available drug. Suramin is a food and drug administration (**FDA**) approved drug that appears to be a readily available medication, since it has anti fibrotic properties, as it prevents **TGF- $\beta$ 1** from initiating its effect on the fibroblasts by competitively binding to its receptors (**Foster et al ., 2003 ; Li et al ., 2004**).


### **Aim of work**

Based on the prior literature, the aim of this study was to investigate and clarify the possible role of suramin on the healing process of skeletal muscle after induced laceration injury in a mice-model using histological, immunohistochemical and morphometric methods.


# Skeletal Muscle

## Skeletal Muscle Development (myogenesis)

All vertebrate skeletal muscles (apart from head muscles) are derived from mesodermal precursor cells originating from the somites (**Diagram 1**) (transient epithelial spheres that pinch out of the paraxial mesoderm lining both sides of the neural tube), to be more specific, skeletal muscle progenitor cells arise from the dermomyotome (**Diagram 2**) (an epithelial layer located in the dorsal compartment of the somite) (**Asakura and Rudnicki, 2002**).



**Diagram(1):**A schematic presentation of a 4-week old human embryo showing somites (**Dequéant and Pourquié, 2008**).



**Diagram(2):**A schematic presentation showing the maturation and compartmentalization of somites (**Eckalbar et al., 2012**).

During embryonic development, specification of mesodermal precursor cells to the myogenic lineage (committed myoblasts) is regulated by several signaling proteins (proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell) such as wingless/integrated protein (WNTS), Sonic hedgehog protein (SHH), Noggin and bone morphometric proteins (BMP4) (**Diagram 3A**). This specification to the myogenic lineage requires the up-regulation of the primary myogenic regulatory factors (MRFs): myogenic differentiation protein (MYOD) and